Phaseline

Companies › Ganzhou Hemay Pharmaceutical

Ganzhou Hemay Pharmaceutical: clinical trials, targets and expected readouts

2 active drug programs in 5 registered trials: 3 Phase 1, 1 Phase 3, 1 Phase 2; Oncology, Immunology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Hemay005
Phosphodiesterase 4 (PDE4) inhibitor
PDE4A, PDE4B, PDE4C, PDE4DPhase 3Behçet's Disease; Moderate to Severe Ulcerative Colitis; PsoriasisDec 2026
Hemay181–Phase 1Solid Tumor; Advanced Solid TumorsAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06376474Hemay005Phase 1PsoriasisImmunologyDec 2025
NCT05749432Hemay181Phase 1Solid TumorOncologyJan 2026
NCT06145893Hemay005Phase 3Behçet's DiseaseImmunologyMay 2026
NCT05486104Hemay005Phase 2Moderate to Severe Ulcerative ColitisImmunologyDec 2026
NCT07446816Hemay181Phase 1Advanced Solid TumorsOncologyAug 2027

Targets

PDE4A (1) PDE4B (1) PDE4C (1) PDE4D (1)

Companies with the same targets

Amgen MediciNova Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA Merck & Co. (MSD) Arcutis Biotherapeutics Integrative Skin Science and Research Shionogi Tetra Discovery Partners

Companies built like this

Integrative Skin Science and Research Arcutis Biotherapeutics Palisade Bio Antengene Biologics Molecure

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.